Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Combe

Showing results (261-270 of 282) with videos related to

Pageof 29
Sort By:
Annals of the Rheumatic Diseases|December 20, 2016
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritisHanna W van Steenbergen, Daniel Aletaha, Liesbeth J J Beaart-van de Voorde, et al.
Rheumatology (Oxford, England)|January 16, 2023
Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAMSofia Ramiro, Robert Landewé, Désirée van der Heijde, et al.
Arthritis and Rheumatism|May 28, 2010
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryBenjamin Terrier, Zahir Amoura, Philippe Ravaud, et al.
Annals of the Rheumatic Diseases|February 24, 2022
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 updateRobert B M Landewé, Féline P B Kroon, Alessia Alunno, et al.
Annals of the Rheumatic Diseases|February 26, 2020
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)Sofia Ramiro, Robert Bm Landewé, Désirée van der Heijde, et al.
The Journal of Rheumatology|September 3, 2019
Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RAWalter P Maksymowych, Oliver FitzGerald, Mikkel Østergaard, et al.
The Journal of Rheumatology|September 17, 2019
Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM CohortAlexandre Sepriano, Sofia Ramiro, Oliver FitzGerald, et al.
Annals of the Rheumatic Diseases|January 23, 2014
Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility geneSteven Gazal, Karim Sacre, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|October 29, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Pageof 29

Showing results (261-270 of 282) with videos related to

Sort By:
Pageof 29
Annals of the Rheumatic Diseases|December 20, 2016
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritisHanna W van Steenbergen, Daniel Aletaha, Liesbeth J J Beaart-van de Voorde, et al.
Rheumatology (Oxford, England)|January 16, 2023
Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAMSofia Ramiro, Robert Landewé, Désirée van der Heijde, et al.
Arthritis and Rheumatism|May 28, 2010
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryBenjamin Terrier, Zahir Amoura, Philippe Ravaud, et al.
Annals of the Rheumatic Diseases|February 24, 2022
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 updateRobert B M Landewé, Féline P B Kroon, Alessia Alunno, et al.
Annals of the Rheumatic Diseases|February 26, 2020
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)Sofia Ramiro, Robert Bm Landewé, Désirée van der Heijde, et al.
The Journal of Rheumatology|September 3, 2019
Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RAWalter P Maksymowych, Oliver FitzGerald, Mikkel Østergaard, et al.
The Journal of Rheumatology|September 17, 2019
Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM CohortAlexandre Sepriano, Sofia Ramiro, Oliver FitzGerald, et al.
Annals of the Rheumatic Diseases|January 23, 2014
Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility geneSteven Gazal, Karim Sacre, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|October 29, 2013
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Pageof 29